topic

215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin
Robyn Puro, Prabir Chakraborty, John Richards, Ronald Hiebsch, Michael Donio, W Casey Wilson, Benjamin Capoccia, Carrie Brachmann, Vicki Sung, Arun Kashyap, Daniel Pereira

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A128-A129; DOI: 10.1136/jitc-2020-SITC2020.0215
216 Anti-tumor activity of iosH2 by blocking LILRB2 receptor signalling
Osiris Marroquin Belaunzaran, Anahita Rafiei, Anil Kumar, Julia Kolibaba, Lorenz Vogt, Sean Smith, Christoph Renner

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A129; DOI: 10.1136/jitc-2020-SITC2020.0216
220 Real-world outcomes of patients with resected stage IIIA melanoma treated with adjuvant nivolumab
Wolfram Samlowski, Robert Nicholas, Tayla Poretta, Andriy Moshyk, Jonathan Rajkumar, Anthony Salvatore, Brian Stwalley, Esmond Nwokeji

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A131; DOI: 10.1136/jitc-2020-SITC2020.0220
221 Poor performance status negatively affects survival benefit of immunotherapy in non-small cell lung cancer
Hameem Kawsar, Pramod Gaudel, Nahid Suleiman, Mohammed Al-Jumayli, Chao Huang, Prakash Neupane

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A131-A132; DOI: 10.1136/jitc-2020-SITC2020.0221
224 Outcomes of stage IV melanoma in the era of immunotherapy: a national cancer database (NCDB) analysis
Tamara Sussman, Wei Wei, Pauline Funchain, Brian Gastman

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A133-A134; DOI: 10.1136/jitc-2020-SITC2020.0224
227 Using 3D spheroid cultures towards personalized ex vivo profiling of immune checkpoint inhibitor efficacy in melanoma and non-small cell lung cancer
Kathryn Appleton, Katy Lassahn, Ashley Elrod, Tessa DesRochers

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A135-A136; DOI: 10.1136/jitc-2020-SITC2020.0227
229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy
Kristina Beeler, Jakob Vowinckel, Martin Soste, Domenico Mallardo, Mariaelena Capone, Madonna Gabriele, Antonio Sorrentino, Vito Vanella, Kamil Sklodowski, Daniel Heinzmann, Paolo Ascierto

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A137; DOI: 10.1136/jitc-2020-SITC2020.0229
230 Single cell PIK3 gene expression patterns support duvelisib (PI3K-delta, gamma inhibitor) treatment of melanoma and other tumors after checkpoint inhibitor therapy
Samantha Hidy, David Weaver

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A137-A138; DOI: 10.1136/jitc-2020-SITC2020.0230
231 A novel discovery pipeline identifies melanoma-specific antibodies in patients responding to immune checkpoint inhibitors
Daniel Delitto, Evan Lipson, Laura Cappelli, Klaus Busam, Antony Rosen, Suzanne Topalian, Livia Casciola-Rosen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A138; DOI: 10.1136/jitc-2020-SITC2020.0231
235 Antigen presentation pathways prime melanoma patients for more durable response to anti–PD-1 checkpoint blockade therapy
Saurabh Garg, Eric Welsh, Bin Fang, Yuliana Hernandez, Trevor Rose, Jhanelle Gray, John Koomen, Anders Berglund, James Mule, Joseph Markowitz

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A139-A140; DOI: 10.1136/jitc-2020-SITC2020.0235

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages